For Reuters Pharma Europe 2025, pharmaphorum is providing coverage courtesy NAVLIN Daily, a pricing and market access insights report from EVERSANA (pharmaphorum's parent company). You can see the ...
The fund bought more USVM, lifting the position to 1.125% of 13F AUM as of December 31, 2025. Top holdings after the filing: IVV: $4.54 billion (6.6% of AUM) AVGO: $2.78 billion (4.0% of AUM) AGG: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback